Tech giants including Google and Microsoft want to work with hospitals and health-care systems to improve lives. But should people trust them with their medical data?
For more from Economist Films visit: http://films.economist.com/
Tech giants including Google and Microsoft want to work with hospitals and health-care systems to improve lives. But should people trust them with their medical data?
For more from Economist Films visit: http://films.economist.com/
Amazon CEO Jeff Bezos and the World Health Organization’s director-general are trading ideas on how to get the COVID-19 pandemic under control, using tools ranging from Amazon Web Services’ firepower in cloud computing and artificial intelligence to distribution channels for coronavirus test kits.
Bezos recapped today’s talk with Director-General Tedros Adhanom Ghebreyesus in an Instagram post, featuring a screengrab of Bezos’ videoconference view with the billionaire’s own visage in the upper right corner of the frame:
By Kurt M. Campbell and Rush Doshi
KURT M. CAMPBELL is Chair and CEO of the Asia Group and was U.S. Assistant Secretary of State for East Asian and Pacific Affairs from 2009 to 2013.
Scientists took conspiracy theories seriously and analyzed the coronavirus to reveal its natural origins.
Officials are working out final details in plans to begin clinical trials next week for a malaria drug combination that appears to hold some promise for confronting the coronavirus pandemic.
New York state Health Department officials are making arrangements to determine what patients at which hospitals will be allowed to participate in trials with hydroxychloroquine, Zithromax and chloroquine, a senior official at the department with knowledge of the plan told ABC News. The bulk of the patients are expected to be in the New York City metro area because the region has the biggest cluster of cases.
New York Gov. Andrew Cuomo announced earlier this week that he was eager to get the trials started. By Tuesday, the drugs were in New York and officials were working to identify who could participate.
The medications, originally developed to fight malaria, have raised hope among many that they could aid in treating coronavirus. The core of the medical therapy is chloroquine, closely related to hydroxychloroquine, which has been used to treat malaria since 1944. It can be given before exposure to malaria to prevent infection, and it can also be given as treatment afterward. It’s also currently used to treat autoimmune diseases like lupus. Doctors are adding the antibiotic Zithromax to the cocktail.
As for coronavirus patients in serious condition, the ministry proposed – in addition to treating respiratory failure and supportive treatment – using Gilead’s drug Remdesivir, which was used in the case of Patient 16. The 38-year-old bus driver from East Jerusalem was in serious condition and the drug improved his situation dramatically, so much so that he was in good condition after the treatment.
They said that research into treating the virus is only in the research stage since the virus was only discovered some months ago.
The 43-year-old scientist is a member of the Technion’s Wolfson Faculty of Chemical Engineering, and his lab first developed a food additive to boost the immune system of animals to protect them from contracting viral diseases. This invention formed the basis of his own commercialized start-up company, ViAqua Therapeutics, which focused the development of the drug on shrimp, as over 30% of the global shrimp population is wiped out yearly by a viral disease known as white spot syndrome.
Israeli scientist and entrepreneur Prof. Avi Schroeder is working on a preventative drug for the coronavirus by adapting a food additive designed for shrimp.
The project is one of the several emergency projects that are the focus of around-the-clock work by 20 different labs at the Technion Institute of Technology to work on coronavirus vaccines, therapeutic treatments, diagnostic methods and patient treatment methods.
The last point is that Taiwan has a very good healthcare system, especially compared with the U.S. Taiwan’s health insurance system is affordable for the general public, which means everyone can get a medical examination or hospital treatment when necessary. It is also a scientific one: The health insurance system collects personal data and medical records, so hospitals and doctors can make good judgments about every patient’s condition. The quality of the national health system is quite important in the healing of patients and the containment of coronavirus.
Taiwan’s coronavirus response so far has been exemplary. Other nations, especially the U.S., should take note, says former Taiwan Premier Jiang Yi-huah.